TRACON Pharmaceuticals Collaborates with National Cancer Institute on Cancer Treatment

Strategic Insights -

TRACON Pharmaceuticals, a biotechnology company, has entered into a Cooperative Research and Development Agreement with the National Cancer Institute to collaborate on the study of TRC105 for the treatment of prostate cancer. TRC105 targets CD105, an endothelial cell membrane receptor essential for angiogenesis, which is critical for tumor growth and metastasis. The 5-year collaboration aims to develop TRC105 as a treatment for prostate cancer, the most common cancer affecting men in the United States. This milestone marks a significant step in the development of TRC105, with Phase 2 clinical trials expected to follow.

Key Takeaways:

  • TRACON Pharmaceuticals has entered into a CRADA with the National Cancer Institute to collaborate on the study of TRC105 for the treatment of prostate cancer.
  • TRC105 targets CD105, an endothelial cell membrane receptor essential for angiogenesis, which is critical for tumor growth and metastasis.
  • The 5-year collaboration aims to develop TRC105 as a treatment for prostate cancer.
  • TRACON Pharmaceuticals has a portfolio of products, including TRC093, a monoclonal antibody that inhibits angiogenesis, and TRC102, a small molecule that reverses resistance to chemotherapeutics.
  • The company has completed Phase 1 clinical trials for TRC093 and TRC105, with TRC102 currently in Phase 1 trials.
  • Bryan Leigh, MD, TRACON's Chief Medical Officer, commented on the significance of the CRADA, stating, "This CRADA is a significant milestone in the development of TRC105."

Statistics:

  • Prostate cancer is the most common cancer affecting men in the United States.
  • TRACON Pharmaceuticals has a 5-year collaboration with the National Cancer Institute to develop TRC105 as a treatment for prostate cancer.
  • TRC105 targets a wide variety of solid cancer types.
  • TRC105 began dosing in a Phase 1 clinical trial in January 2008.
  • TRC093 began dosing in a Phase 1 clinical trial in July 2007.
  • TRC102 began dosing in a Phase 1 trial in 2008.

Sources:

  • GlobeNewswire via COMTEX, October 19, 2009
  • Tracon Pharmaceuticals, Inc.